Search Results - "KOSCHINSKY, M. L"

Lipoprotein(a) as a risk factor for coronary artery disease by Marcovina, Santica M, Koschinsky, Marlys L

“…Since its identification by Kåre Berg in 1963, lipoprotein(a) [Lp(a)] has become a focus of research interest owing to the results of case-control and…”
Get full text

Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100 by Koschinsky, M.L, Cote, G.P, Gabel, B, Hoek, Y.Y. van der

“…We have utilized a recombinant expression system in order to study the assembly of lipoprotein(a) (Lp(a)) particles. Using a 17-kringle recombinant form of…”
Get full text

Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a) by Marcovina, S M, Albers, J J, Gabel, B, Koschinsky, M L, Gaur, V P

“…Lipoprotein(a) [Lp(a)] has been measured in numerous clinical and epidemiological studies by a variety of immunochemical methods. However, little, if any,…”
Get more information

The relationship between lipoprotein(a) and the complications of diabetes mellitus by KOSCHINSKY, M. L, MARCOVINA, S. M

“…The risk of cardiovascular disease is increased approximately two- to four-fold in patients with diabetes mellitus compared with non-diabetic controls. The…”
Get full text

Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a) by CHIESA, G, HOBBS, H. H, KOSCHINSKY, M. L, LAWN, R. M, MAIKA, S. D, HAMMER, R. E

“…Lipoprotein(a) (Lp(a)) is an atherosclerosis-causing lipoprotein that circulates in human plasma as a complex of low density lipoprotein (LDL) and…”
Get full text

Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a) by Scipione, C. A., McAiney, J. T., Simard, D. J., Bazzi, Z. A., Gemin, M., Romagnuolo, R., Macrae, F. L., Ariëns, R. A., Hegele, R. A., Auld, J., Gauld, J. W., Boffa, M. B., Koschinsky, M. L.

“…Essentials Elevated lipoproteinp(a) is an independent and causal risk factor for atherothrombotic diseases. rs3798220 (Ile/Met substitution in apo(a)…”
Get full text

Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? by Marcovina, S M, Koschinsky, M L

Get full text

Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure by Koschinsky, ML, Boffa, MB, Nesheim, ME, Zinman, B, Hanley, AJG, Harris, SB, Cao, H, Hegele, RA

“…Thrombin‐activable fibrinolysis inhibitor (TAFI) is a hepatically secreted zymogen, whose substrates include bradykinin. The CPB2 gene encoding TAFI is a…”
Get full text

Apolipoprotein(a) inhibits the conversion of Glu‐plasminogen to Lys‐plasminogen: a novel mechanism for lipoprotein(a)‐mediated inhibition of plasminogen activation by FERIC, N. T., BOFFA, M. B., JOHNSTON, S. M., KOSCHINSKY, M. L.

“…Background: Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are associated with an increased risk for thrombotic disorders. Lp(a) is a unique…”
Get full text

The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms by van der Hoek, Y Y, Wittekoek, M E, Beisiegel, U, Kastelein, J J, Koschinsky, M L

“…Elevated levels of plasma lipoprotein(a) [Lp(a)] have been correlated with the development of atherosclerosis in human populations. Apolipoprotein(a) [apo(a);…”
Get more information

Defensin promotes the binding of lipoprotein(a) to vascular matrix by BDEIR, K, CANE, W, HANCOCK, M. A, TOMASZEWSKI, J, RAGHUNATH, P. N, GANZ, T, HIGAZI, A. A.-R, CINES, D. B, CANZIANI, G, CHAIKEN, I, WEISEL, J, KOSCHINSKY, M. L, LAWN, R. M, BANNERMAN, P. G, SACHAIS, B. S, KUO, A

“…Retention of lipoproteins within the vasculature is a central event in the pathogenesis of atherosclerosis. However, the signals that mediate this process are…”
Get full text

Lipoprotein(a) Assembly: Quantitative Assessment of the Role of Apo(a) Kringle IV Types 2-10 in Particle Formation by Gabel, Brent R, May, Lorraine F, Marcovina, Santica M, Koschinsky, Marlys L

“…We have developed a system for the quantitative assessment of the efficiency of lipoprotein(a) [Lp(a)] formation in vitro. Amino-terminally truncated…”
Get full text

Evidence mounts for a role of the kidney in lipoprotein(a) catabolism by Albers, J.J., Koschinsky, M.L., Marcovina, S.M.

“…Numerous studies have suggested a role of the kidney in lipoprotein(a) (Lp(a)) catabolism, but direct evidence is still lacking. Frischmann et al. demonstrate…”
Get full text

Apolipoprotein(a) Enhances Platelet Responses to the Thrombin Receptor-Activating Peptide SFLLRN by Rand, Margaret L, Sangrar, Waheed, Hancock, Mark A, Taylor, Desiree M, Marcovina, Santica M, Packham, Marian A, Koschinsky, Marlys L

“…Elevated levels of lipoprotein(a) [Lp(a)] are correlated with an increased risk of atherosclerotic disease. We examined the effect of recombinant…”
Get full text

Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells by Lin, J H H, Garand, M, Zagorac, B, Schadinger, S L, Scipione, C, Koschinsky, M L, Boffa, M B

“…TAFI (thrombin-activatable fibrinolysis inhibitor) is a carboxypeptidase zymogen originally identified in plasma. The TAFI pathway helps to regulate the…”
Get more information

Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3′‐untranslated region by NOVAKOVIC, D., KUO, A. C. Y., LIN, J. H., KOSCHINSKY, M. L., BOFFA, M. B.

“…Background:  Thrombin‐activatable fibrinolysis inhibitor (TAFI) is a basic carboxypeptidase zymogen encoded by the human gene CPB2. TAFI constitutes a…”
Get full text

The Structure of Lipoprotein(a) and Ligand-Induced Conformational Changes by Weisel, John W, Nagaswami, Chandrasekaran, Woodhead, John L, Higazi, Abd Al-Roof, Cain, William J, Marcovina, Santica M, Koschinsky, Marlys L, Cines, Douglas B, Bdeir, Khalil

“…Lipoprotein(a) is composed of low-density lipoprotein linked both covalently and noncovalently to apolipoprotein(a). The structure of lipoprotein(a) and the…”
Get full text

Complete cDNA Sequence of Human Preceruloplasmin by Koschinsky, Marlys L., Funk, Walter D., Van Oost, Bernard A., Ross T. A. Mac Gillivray

“…A cDNA for human ceruloplasmin (EC 1.16.3.1) was identified in a human liver cDNA library by screening with two mixtures of synthetic oligodeoxyribonucleotides…”
Get full text

Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac‐1 integrin by Sotiriou, Sotirios N., Orlova, Valeria V., Al‐Fakhri, Nadia, Ihanus, Eveliina, Economopoulou, Matina, Isermann, Berend, Bdeir, Khalil, Nawroth, Peter P., Preissner, Klaus T., Gahmberg, Carl G., Koschinsky, Marlys L., Chavakis, Triantafyllos

“…Lipoprotein(a) [Lp(a)], consisting of LDL and the unique constituent apolipoprotein(a) [apo(a)], which contains multiple repeats resembling plasminogen kringle…”
Get full text

Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo by BIEMOND, B. J, FRIEDERICH, P. W, KOSCHINSKY, M. L, LEVI, M, SANGRAR, W, XIA, J, BÜLLER, H. R, TEN CATE, J. W

“…In many case-control as well as epidemiological studies, increased lipoprotein(a) [Lp(a)] levels are considered to constitute an independent risk factor for…”
Get full text